The Randomized Embedded Multifactorial Adaptive Platform Trial in Community-acquired Pneumonia (REMAP-CAP): Building an International Research Response to Variant COVID-19
社区获得性肺炎随机嵌入式多因素自适应平台试验 (REMAP-CAP):针对变种 COVID-19 建立国际研究响应
基本信息
- 批准号:449021
- 负责人:
- 金额:$ 72.85万
- 依托单位:
- 依托单位国家:加拿大
- 项目类别:Operating Grants
- 财政年份:2021
- 资助国家:加拿大
- 起止时间:2021-04-01 至 2022-04-01
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
Information about the best treatments for patients with COVID-19 is being generated at a record pace. Large international clinical trials have been central to this process. REMAP-CAP - the Randomized Embedded Multifactorial Adaptive Platform Trial in Co
有关COVID-19患者最佳治疗方法的信息正在以创纪录的速度生成。 大型国际临床试验是这一过程的核心。 REMAP-CAP -随机嵌入式多因素自适应平台试验
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Marshall John C其他文献
Marshall John C的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Marshall John C', 18)}}的其他基金
The Randomized Embedded Multifactorial Adaptive Platform Trial in Community-Acquired Pneumonia (REMAP-CAP): Enshrining a Global Pandemic Research Response to COVID-19 and Beyond
社区获得性肺炎随机嵌入式多因素自适应平台试验 (REMAP-CAP):确立针对 COVID-19 及其他疾病的全球流行病研究应对措施
- 批准号:
474661 - 财政年份:2022
- 资助金额:
$ 72.85万 - 项目类别:
Operating Grants
The Randomized Embedded Multifactorial Adaptive Platform Trial in Community-Acquired Pneumonia (REMAP-CAP): Enshrining a Global Pandemic Research Response to COVID-19 and Beyond
社区获得性肺炎随机嵌入式多因素自适应平台试验 (REMAP-CAP):确立针对 COVID-19 及其他疾病的全球流行病研究应对措施
- 批准号:
480744 - 财政年份:2022
- 资助金额:
$ 72.85万 - 项目类别:
Operating Grants
The International Forum for Acute Care Trialists (InFACT): Shaping the next decade of global acute care research collaboration
国际急症护理试验者论坛 (InFACT):塑造全球急症护理研究合作的下一个十年
- 批准号:
412137 - 财政年份:2019
- 资助金额:
$ 72.85万 - 项目类别:
Miscellaneous Programs
The Role of Active Deresuscitation After Resuscitation (RADAR): A pilot randomized clinical trial
复苏后主动断气 (RADAR) 的作用:一项试点随机临床试验
- 批准号:
390576 - 财政年份:2018
- 资助金额:
$ 72.85万 - 项目类别:
Operating Grants
Canadian Adaptive Platform Trial in Intensive Care (CAPTIC) Program
加拿大重症监护适应性平台试验 (CAPTIC) 计划
- 批准号:
379271 - 财政年份:2018
- 资助金额:
$ 72.85万 - 项目类别:
Operating Grants
The Antimicrobial Resistance in Intensive Care (AMRIC) Network: A global surveillance network to monitor the role of the ICU environment in the emergence of AMR; Phase I
重症监护中的抗菌素耐药性 (AMRIC) 网络:一个全球监测网络,用于监测 ICU 环境在抗菌素耐药性出现中的作用;
- 批准号:
350919 - 财政年份:2016
- 资助金额:
$ 72.85万 - 项目类别:
Operating Grants
Pandemic Preparedness in the Interpandemic Period: ISARIC, InFACT and the Global Response to Emerging Infectious Disease Threats
大流行间期的大流行准备:ISARIC、InFACT 和全球对新出现的传染病威胁的应对措施
- 批准号:
246114 - 财政年份:2011
- 资助金额:
$ 72.85万 - 项目类别:
Miscellaneous Programs
Collaborative H1N1 Adjuvant Treatment (CHAT) Pilot Trial
H1N1 协作辅助治疗 (CHAT) 试点试验
- 批准号:
198064 - 财政年份:2009
- 资助金额:
$ 72.85万 - 项目类别:
Operating Grants
Characterization of a novel, caspase-8 dependent survival pathway in inflammatory neutrophils
炎症性中性粒细胞中新型 caspase-8 依赖性生存途径的表征
- 批准号:
172386 - 财政年份:2008
- 资助金额:
$ 72.85万 - 项目类别:
Operating Grants
相似海外基金
COVID-19 Immunologic Antiviral therapy with Omalizumab (CIAO trial) - An Adaptive Phase II Randomized-Controlled Clinical Trial
使用奥马珠单抗进行 COVID-19 免疫抗病毒治疗(CIAO 试验)——适应性 II 期随机对照临床试验
- 批准号:
475843 - 财政年份:2022
- 资助金额:
$ 72.85万 - 项目类别:
Studentship Programs
COVID-19 Immunologic Antiviral therapy with Omalizumab (CIAO trial) - An Adaptive Phase II Randomized-Controlled Clinical Trial
使用奥马珠单抗进行 COVID-19 免疫抗病毒治疗(CIAO 试验)——适应性 II 期随机对照临床试验
- 批准号:
474485 - 财政年份:2022
- 资助金额:
$ 72.85万 - 项目类别:
Studentship Programs
Phase 2 COVID-19 Vaccine Variant Clinical Trial
COVID-19 疫苗变体 2 期临床试验
- 批准号:
10683817 - 财政年份:2022
- 资助金额:
$ 72.85万 - 项目类别:
Statistical and Data Coordinating Center: SARS-CoV-2/COVID-19 Clinical Trial Support for research activities
统计和数据协调中心:SARS-CoV-2/COVID-19 临床试验研究活动支持
- 批准号:
10788028 - 财政年份:2021
- 资助金额:
$ 72.85万 - 项目类别:
THE SEARCH FOR COVID-19 PREVENTION AND CURE: ADDRESSING THE CRITICAL ROLE OF INNATE/ADAPTIVE IMMUNITY BY INTEGRATING NOVEL INFORMATICS, TRANSLATIONAL TECHNOLOGIES, AND ONGOING CLINICAL TRIAL RESEARCH
寻找 COVID-19 的预防和治疗:通过整合新颖的信息学、翻译技术和正在进行的临床试验研究来解决先天/适应性免疫的关键作用
- 批准号:
10158982 - 财政年份:2020
- 资助金额:
$ 72.85万 - 项目类别:
ANTI-THROMBOTIC THERAPY TO AMELIORATE COMPLICATIONS OF COVID-19 (ATTACC): A randomized, international, multi-centre, adaptive, controlled clinical trial
改善 COVID-19 并发症的抗血栓治疗 (ATTACC):一项随机、国际、多中心、适应性、对照临床试验
- 批准号:
429655 - 财政年份:2020
- 资助金额:
$ 72.85万 - 项目类别:
Operating Grants
Central IRB Services for NIAID Coronavirus COVID-19 OWS ACTIV-3 Clinical Trial
NIAID 冠状病毒 COVID-19 OWS ACTIV-3 临床试验的中央 IRB 服务
- 批准号:
10274221 - 财政年份:2020
- 资助金额:
$ 72.85万 - 项目类别:
Semaglutide to reduce Myocardial injury in PATIents with COVID-19 (SEMPATICO): An exploratory randomized controlled clinical trial
索马鲁肽可减少 COVID-19 患者的心肌损伤 (SEMPATICO):一项探索性随机对照临床试验
- 批准号:
429612 - 财政年份:2020
- 资助金额:
$ 72.85万 - 项目类别:
Operating Grants
COVID-19: multi-arm, multi stage adaptive clinical trial (CoV-MAMS)
COVID-19:多组、多阶段适应性临床试验(CoV-MAMS)
- 批准号:
MC_PC_19056 - 财政年份:2020
- 资助金额:
$ 72.85万 - 项目类别:
Intramural
Anti-Coronavirus Therapy (ACT) to prevent COVID-19 disease progression: a clinical trial platform
预防 COVID-19 疾病进展的抗冠状病毒治疗 (ACT):临床试验平台
- 批准号:
429561 - 财政年份:2020
- 资助金额:
$ 72.85万 - 项目类别:
Operating Grants